Posted by Michael Wonder on 16 Jun 2023
GSK announces extension of FDA review period for momelotinib
16 June 2023 - GSK today announced that the US FDA has extended the review period of the new drug application for momelotinib by three months to provide time to review recently submitted data.
The extended action date is 16 September 2023.
